Evidence map›Paper›PMID 32867356›Full record

ArticleMolecules (Basel, Switzerland)2020

Evaluation of Supercritical CO

Elvira R Gafarova, Ekaterina A Grebenik, Alexey E Lazhko, Anastasia A Frolova, Anastasia S Kuryanova, Alexandr V Kurkov, Ilya A Bazhanov, Byron S Kapomba, Nastasia V Kosheleva, Ivan A Novikov and 4 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Elvira R GafarovaInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Ekaterina A GrebenikInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-0763-2903
Alexey E LazhkoKurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, 119991 Moscow, Russia.
Anastasia A FrolovaInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Anastasia S KuryanovaInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Alexandr V KurkovInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-6258-3067
Ilya A BazhanovInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Byron S KapombaInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.ORCID 0000-0002-7785-6865
Nastasia V KoshelevaFSBSI "Institute of General Pathology and Pathophysiology", 125315 Moscow, Russia.
Ivan A NovikovScientific Research Institute of Eye Diseases, 119021 Moscow, Russia.
Anatoly B ShekhterInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Elena N GolubevaFaculty of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
Anna B SoloviovaN. N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, 117977 Moscow, Russia.
Peter S TimashevInstitute for Regenerative Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Sechenov University · RULomonosov Moscow State University · RUFederal State Scientific Institution Research Institute of Eye Diseases · RUNS Kurnakova Institute of General and Inorganic Chemistry · RUSemenov Institute of Chemical Physics · RU

Funding

Russian academic excellence project "5-100"Russian Foundation for Basic Research 18-29-06059State Assignment theme V. 46.14, Grant Nos. 0082-2014-0006 and AAAA-A17-117-117032750202-6
6 · The paper itself

Abstract

One of the leading trends in the modern tissue engineering is the development of new effective methods of decellularization aimed at the removal of cellular components from a donor tissue, reducing its immunogenicity and the risk of rejection. Supercritical CO

Indexed as

Cellular StructuresAnimalsAortic ValveCarbon DioxideCells, CulturedElastic ModulusExtracellular MatrixHumansMesenchymal Stem CellsSheepTensile StrengthTissue EngineeringCarbon Dioxideaortic valvebiomaterialsbiomedical engineeringdecellularizationsupercritical CO2

Identifiers

PMID32867356
PMCPMC7504408
OpenAlexW3080940991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.